Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA2DS2-VASc Score 0–1: A Korean Multi-Center Cohort
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Moonki | - |
dc.contributor.author | Byeon, Kyeongmin | - |
dc.contributor.author | Kang, K.-W. | - |
dc.contributor.author | Park, Y.M. | - |
dc.contributor.author | Hwang, Y.M. | - |
dc.contributor.author | Lee, S.H. | - |
dc.contributor.author | Jin, E.-S. | - |
dc.contributor.author | Roh, S.-Y. | - |
dc.contributor.author | Kim, J.S. | - |
dc.contributor.author | Ahn, J. | - |
dc.contributor.author | Lee, S.-R. | - |
dc.contributor.author | Choi, E.-K. | - |
dc.contributor.author | Ahn, M.-S. | - |
dc.contributor.author | Lee, E.M. | - |
dc.contributor.author | Park, H.-C. | - |
dc.contributor.author | Lee, K.H. | - |
dc.contributor.author | Kim, M. | - |
dc.contributor.author | Choi, J.H. | - |
dc.contributor.author | Ko, J.S. | - |
dc.contributor.author | Kim, J.B. | - |
dc.contributor.author | Kim, C. | - |
dc.contributor.author | Lip, G.Y.H. | - |
dc.contributor.author | Shin, Seung Yong | - |
dc.date.accessioned | 2024-02-26T03:00:54Z | - |
dc.date.available | 2024-02-26T03:00:54Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.issn | 1976-2437 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/72429 | - |
dc.description.abstract | Purpose: Atrial fibrillation (AF) patients with low to intermediate risk, defined as non-gender CHA2DS2-VASc score of 0–1, are still at risk of stroke. This study verified the usefulness of ABCD score [age (≥60 years), B-type natriuretic peptide (BNP) or N-ter-minal pro-BNP (≥300 pg/mL), creatinine clearance (<50 mL/min/1.73 m2), and dimension of the left atrium (≥45 mm)] for stroke risk stratification in non-gender CHA2DS2-VASc score 0–1. Materials and Methods: This multi-center cohort study retrospectively analyzed AF patients with non-gender CHA2DS2-VASc score 0–1. The primary endpoint was the incidence of stroke with or without antithrombotic therapy (ATT). An ABCD score was validated. Results: Overall, 2694 patients [56.3±9.5 years; female, 726 (26.9%)] were followed-up for 4.0±2.8 years. The overall stroke rate was 0.84/100 person-years (P-Y), stratified as follows: 0.46/100 P-Y for an ABCD score of 0; 1.02/100 P-Y for an ABCD score ≥1. The ABCD score was superior to non-gender CHA2DS2-VASc score in the stroke risk stratification (C-index=0.618, p=0.015; net reclassi-fication improvement=0.576, p=0.040; integrated differential improvement=0.033, p=0.066). ATT was prescribed in 2353 patients (86.5%), and the stroke rate was significantly lower in patients receiving non-vitamin K antagonist oral anticoagulant (NOAC) therapy and an ABCD score ≥1 than in those without ATT (0.44/100 P–Y vs. 1.55/100 P-Y; hazard ratio=0.26, 95% confidence interval 0.11–0.63, p=0.003). Conclusion: The biomarker-based ABCD score demonstrated improved stroke risk stratification in AF patients with non-gender CHA2DS2-VASc score 0–1. Furthermore, NOAC with an ABCD score ≥1 was associated with significantly lower stroke rate in AF patients with non-gender CHA2DS2-VASc score 0–1. © Yonsei University College of Medicine 2022. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Yonsei University College of Medicine | - |
dc.title | Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA2DS2-VASc Score 0–1: A Korean Multi-Center Cohort | - |
dc.type | Article | - |
dc.identifier.doi | 10.3349/ymj.2022.0157 | - |
dc.identifier.bibliographicCitation | Yonsei Medical Journal, v.63, no.10, pp 892 - 901 | - |
dc.identifier.kciid | ART002878036 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000944459400002 | - |
dc.identifier.scopusid | 2-s2.0-85138966136 | - |
dc.citation.endPage | 901 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 892 | - |
dc.citation.title | Yonsei Medical Journal | - |
dc.citation.volume | 63 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | ABCD score | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | risk stratification | - |
dc.subject.keywordAuthor | stroke | - |
dc.subject.keywordPlus | BRAIN NATRIURETIC PEPTIDE | - |
dc.subject.keywordPlus | NET CLINICAL BENEFIT | - |
dc.subject.keywordPlus | RISK-FACTOR | - |
dc.subject.keywordPlus | ANTITHROMBOTIC THERAPY | - |
dc.subject.keywordPlus | ORAL ANTICOAGULANTS | - |
dc.subject.keywordPlus | PREDICTING STROKE | - |
dc.subject.keywordPlus | APIXABAN | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.